SCHEMBL5342131

SCHEMBL5342131

CCCC(=O)NS(=O)(=O)CCC(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
CTSD P07339 1/20 0.38
PPARG P37231 2/20 0.36
PSMB5 P28074 1/20 0.34
KCNA5 P22460 1/20 0.34
CA1 P00915 3/20 0.33
POLB P06746 1/20 0.33
CA12 O43570 1/20 0.33
CA2 P00918 1/20 0.33
CA9 Q16790 1/20 0.33
CASP2 P42575 1/20 0.32
CNR1 P21554 1/20 0.32
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
FAAH O00519 1/20 0.32
MAPK1 P28482 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3351216 0.85 KCNA5 (0.35) PPARGPSMB5KCNA5CA1POLB
Hydrochloric Acid SCHEMBL3349174 0.83 KCNA5 (0.35) PPARGPSMB5KCNA5CA1POLB
SCHEMBL16181065 0.82 PLA2G10 (0.37) PPARGCNR1MEN1KMT2AFAAH
SCHEMBL7991035 0.82 HDAC3 (0.46) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL16181067 0.81 FAAH (0.40) PPARGCNR1MEN1KMT2AFAAH
SCHEMBL27109977 0.79 CASP2 (0.44) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL6309191 0.78 HDAC3 (0.50) HDAC3HDAC1HDAC2HDAC8HDAC6
SCHEMBL27716389 0.76 CYP2D6 (0.38) PPARGKCNA5CA1POLBMEN1
SCHEMBL13773143 0.75 ALDH1A1 (0.37) PPARGKCNA5CA1CA12CA2
SCHEMBL20467383 0.74 AKR1B1 (0.43) HDAC3HDAC1HDAC2HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-2004502669-A 2004-01-29 JP claimed
EP-1353898-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE Elan Pharmaceuticals, Inc. (US) 2003-10-22 EP claimed
WO-2002002512-A2 COMPOUNDS TO TREAT ALZHEIMER'S DISEASE ELAN PHARMACEUTICALS, INC. (US) 2002-01-10 WO claimed
US-20070213407-A1 Compounds to treat Alzheimer's disease ELAN PHARMACEUTICALS AND PHARMACIA & UPJOHN COMPANY LLC 2007-09-13 US disclosed
US-7214715-B2 Compounds to treat Alzheimer's disease PHARMACIA & UPJOHN (US) 2007-05-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213407-A1 Compounds to treat Alzheimer's disease PSEN2, PSEN1, CHAT HDAC3 2174/4885HDAC1 1304/4885HDAC2 1619/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.